Skip to main content
TipRanks
Go Ultimate75% OFF

Knight Therapeutics (GUD) Income Statement

112 Followers

Knight Therapeutics Income Statement

Last quarter (Q3 2026), Knight Therapeutics's total revenue was C$137.69M, an increase of 13.28% from the same quarter last year. In Q3, Knight Therapeutics's net income was C$-2.68M. See Knight Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement
Income StatementDec 25Dec 24Dec 23Dec 22Dec 21
C$ 450.09MC$ 371.30MC$ 328.20MC$ 293.56MC$ 243.48M
C$ 150.74MC$ 174.41MC$ 152.65MC$ 138.06MC$ 115.41M
C$ 152.94MC$ 167.01MC$ 155.54MC$ 155.12MC$ 128.24M
Depreciation and AmortizationC$ 56.57MC$ 53.11MC$ 50.40MC$ 62.62MC$ 47.91M
C$ 54.37MC$ 64.38MC$ 40.90MC$ 25.26MC$ 42.59M
C$ -2.20MC$ 7.40MC$ -2.89MC$ -2.40MC$ -5.32M
C$ -4.50MC$ -5.34MC$ -19.10MC$ -2.92MC$ 19.52M
C$ -6.70MC$ 2.05MC$ -21.99MC$ -43.96MC$ 6.69M
C$ -5.37MC$ 4.33MC$ -16.84MC$ -29.89MC$ 15.68M
Per Share Metrics
Basic EPSC$ -0.05C$ 0.04C$ -0.16C$ -0.26C$ 0.13
Diluted EPSC$ -0.05C$ 0.04C$ -0.16C$ -0.26C$ 0.13
Weighted Average Shares Outstanding99.57M101.04M107.47M114.89M124.48M
Weighted Average Shares Outstanding (Diluted)99.57M101.44M107.47M114.89M124.52M

Currency in CAD

Knight Therapeutics Earnings and Revenue History

-250M0250M500M-120 %0 %120 %240 %EarningsProfit Margin201720182019202020212022202320242025RevenueEarningsProfit Margin